title: New Therapeutic Approaches to the Treatment of Dyslipidemia.
abstract: Dyslipidemia is a risk factor for atherosclerotic cardiovascular disease (ASCVD). Abundant data indicate that low-density lipoproteins (LDL) are causal for ASCVD; a new class of LDL-lowering medicines, the PCSK9 inhibitors, will address much unmet medical need. Human genetics suggest that triglyceride-rich lipoproteins (TRL) are pro-atherogenic and have pointed to a number of protein regulators of lipoprotein lipase activity that are candidates for therapeutic targeting. Finally, high-density lipoprotein (HDL) cholesterol does not appear to be causally associated with protection from ASCVD, reinforced by the failure of three CETP inhibitors in CV outcome trials, but HDL function remains of interest.
authors: Departments of Genetics and Medicine and Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: rader@upenn.edu.
authors: Daniel J
authors: DJ
authors: Rader
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000097:blood / Q000517:prevention & control; D008076:Cholesterol, HDL / Q000097:blood; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000091362:PCSK9 Inhibitors; D015842:Serine Proteinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000071449:Proprotein Convertase 9
chemical_list: D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D000091362:PCSK9 Inhibitors; D015842:Serine Proteinase Inhibitors; C472125:PCSK9 protein, human; D000071449:Proprotein Convertase 9